TGFB1 and hepatocellular carcinoma: Given the complexity of the TME in HCC, combinatorial therapies can include ICIs, agents targeting immunosuppressive immune cells, anti-VEGF inhibitors, anti-TGF-β antibodies, microbiota manipulation, and metabolism intervention.